Skip to search formSkip to main contentSkip to account menu

encorafenib

National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

CarbamatesSulfonamides

Narrower (1)

LGX818

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of…
4039 Background: In the BEACON CRC study, the triplet regimen of encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX… 
2020
2020
Severe pyrexia from nivolumab‐resistant advanced melanoma after successful combined therapy with encorafenib plus binimetinib
Various serious adverse events (AE) have been reported to occur at a high rate in patients treated with BRAF plus mitogen… 
2019
2019
Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma.
10012Background: Treatment of patients with BRAF V600–mutant melanoma includes BRAF/MEK-inhibitor combinations based on… 
2019
2019
Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).
688 Background: BRAFV600E mutation occurs in 10%-–15% of patients (pts) with mCRC and confers a poor prognosis. After first-line… 
2019
2019
Encorafenib inhibits migration, induces cell cycle arrest and apoptosis in colorectal cancer cells
Encorafenib, a new-generation BRAF inhibitor, has been approved by FDA for the treatment of melanoma in combination with… 
2018
2018
Encorafenib plus binimetinib: an embarrassment of riches.
Review
2017
Review
2017
In the pipeline: encorafenib and binimetinib in BRAF-mutated melanoma.
KF Like other combinations of BRAF and MEK inhibitors, encorafenib/binimetinib has been dem­ on strated to be superior to… 
Review
2017
Review
2017
Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?
ABSTRACT Introduction: Historically, there were few effective and durable treatments for metastatic melanoma. Recently, mutation… 
2015
2015
PD-1 inhibitors effective in hodgkin lymphoma.
2015
2015
Abstract CT136: Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the α-specific PI3K inhibitor alpelisib…
Background: Although BRAF V600-mutated (BRAFm) colorectal carcinoma (CRC) does not generally respond to BRAF inhibitors, results… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)